1. Home
  2. NTLA
  3. NTLA News

Latest Intellia Therapeutics Inc. (NTLA) News on May 11, 2025

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report
NTLA

Simply Wall St.

9 hours ago

Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts
NTLA

Simply Wall St.

a day ago

News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA

Zacks

2 days ago

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

NTLA

MT Newswires

2 days ago

Truist Securities Cuts Price Target on Intellia Therapeutics to $33 From $50, Maintains Buy Rating

NTLA

MT Newswires

2 days ago

RBC Trims Price Target on Intellia Therapeutics to $30 From $32, Keeps Outperform, Speculative Risk

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...
NTLA

GuruFocus.com

3 days ago

Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...

NTLA

Morningstar Research

3 days ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
NTLA

Zacks

3 days ago

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
NTLA

GlobeNewswire

3 days ago

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

5 days ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
NTLA

Zacks

5 days ago

CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NTLA

Zacks

6 days ago

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
NTLA

Zacks

10 days ago

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average
NTLA

Zacks

10 days ago

Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates
NTLA

GlobeNewswire

10 days ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
NTLA

Motley Fool

11 days ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet
NTLA

Zacks

12 days ago

Wall Street Analysts Think Intellia Therapeutics (NTLA) Could Surge 392.81%: Read This Before Placing a Bet

Trump’s FDA Sends a Bullish Signal to Biotech
NTLA

The Wall Street Journal

20 days ago

Trump’s FDA Sends a Bullish Signal to Biotech

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
NTLA

Investor's Business Daily

20 days ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

NTLA

MT Newswires

20 days ago

Intellia Therapeutics Shares Rise After Upgrade From Wolfe Research

NTLA

MT Newswires

20 days ago

Wolfe Research Upgrades Intellia Therapeutics to Outperform From Peer Perform, Price Target is $21

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple
NTLA

Insider Monkey

a month ago

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
NTLA

Clinical Trials Arena

a month ago

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

a month ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility
NTLA

Pharmaceutical Technology

a month ago

IO360 Summit: Improving CAR-T cell therapy manufacture and accessibility

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
NTLA

GlobeNewswire

a month ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

NTLA

MT Newswires

a month ago

RBC Cuts Price Target on Intellia Therapeutics to $32 From $37, Keeps Outperform, Speculative Risk

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?
NTLA

Insider Monkey

a month ago

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy?

Biotech stocks slide as Marks resignation seen being negative for sector
NTLA

TipRanks

a month ago

Biotech stocks slide as Marks resignation seen being negative for sector

Intellia Focuses on Pipeline Development Amid Stiff Competition
NTLA

Zacks

a month ago

Intellia Focuses on Pipeline Development Amid Stiff Competition

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
NTLA

Zacks

a month ago

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

NTLA

MT Newswires

2 months ago

Intellia Therapeutics' Gene-Editing Drug Gets FDA Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
NTLA

GlobeNewswire

2 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
NTLA

Motley Fool

2 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls
NTLA

The Fly

2 months ago

Royal Caribbean upgraded, AppLovin downgraded: Wall Street's top analyst calls

NTLA

MT Newswires

2 months ago

HC Wainwright Initiates Intellia Therapeutics at Buy With $30 Price Target

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

2 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA

MT Newswires

2 months ago

Truist Securities Adjusts Intellia Therapeutics Price Target to $50 From $90, Maintains Buy Rating

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
NTLA

Simply Wall St.

2 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y
NTLA

Zacks

2 months ago

NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations
NTLA

Simply Wall St.

2 months ago

Intellia Therapeutics Full Year 2024 Earnings: Beats Expectations

NTLA

MT Newswires

2 months ago

RBC Cuts Price Target on Intellia Therapeutics to $37 From $47, Keeps Outperform, Speculative Risk

NTLA

MT Newswires

2 months ago

JPMorgan Downgrades Intellia Therapeutics to Neutral, Price Target is $13

NTLA

Morningstar Research

2 months ago

Analyst Report: Intellia Therapeutics, Inc.

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...
NTLA

GuruFocus.com

2 months ago

Intellia Therapeutics Inc (NTLA) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

NTLA

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Intellia Therapeutics Inc Earnings Call

NTLA

MT Newswires

2 months ago

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
NTLA

Zacks

2 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress
NTLA

GlobeNewswire

2 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
NTLA

Zacks

3 months ago

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

What's in Store for These 5 Biotech Stocks This Earnings Season?
NTLA

Zacks

3 months ago

What's in Store for These 5 Biotech Stocks This Earnings Season?

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
NTLA

Motley Fool

3 months ago

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
NTLA

Zacks

3 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?
NTLA

Zacks

3 months ago

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
NTLA

GlobeNewswire

3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently
NTLA

Insider Monkey

3 months ago

Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
NTLA

Zacks

3 months ago

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025
NTLA

Insider Monkey

3 months ago

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

3 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA

MT Newswires

3 months ago

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

NTLA

MT Newswires

3 months ago

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

NTLA

MT Newswires

3 months ago

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
NTLA

Clinical Trials Arena

4 months ago

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
NTLA

Zacks

4 months ago

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

NTLA

MT Newswires

4 months ago

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
NTLA

GlobeNewswire

4 months ago

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia makes progress on HAE study; 2 more China drug deals
NTLA

BioPharma Dive

4 months ago

Intellia makes progress on HAE study; 2 more China drug deals

Intellia Loses 21.6% in a Week: How Should You Play the Stock?
NTLA

Zacks

4 months ago

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
NTLA

Zacks

4 months ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
NTLA

Zacks

4 months ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
NTLA

Pharmaceutical Technology

4 months ago

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
NTLA

TipRanks

4 months ago

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo
NTLA

TipRanks

4 months ago

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

Why Is Intellia Therapeutics Stock Trading Lower On Friday?
NTLA

Benzinga

4 months ago

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down
NTLA

Zacks

4 months ago

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Intellia to stop work on rare disease therapy, lay off staff
NTLA

BioPharma Dive

4 months ago

Intellia to stop work on rare disease therapy, lay off staff

NTLA

MT Newswires

4 months ago

Intellia Therapeutics to Workforce by 27%, Halt Some Programs

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
NTLA

GlobeNewswire

4 months ago

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

NTLA

MT Newswires

4 months ago

BofA Securities Adjusts Price Target on Intellia Therapeutics to $50 From $58, Maintains Buy Rating

NTLA

MT Newswires

4 months ago

RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

4 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
NTLA

Insider Monkey

4 months ago

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?
NTLA

Insider Monkey

4 months ago

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation
NTLA

Simply Wall St.

5 months ago

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Intellia Crashes 60% in a Year: How Should You Play the Stock?
NTLA

Zacks

5 months ago

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers
NTLA

Insider Monkey

5 months ago

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NTLA

GlobeNewswire

5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
NTLA

Zacks

6 months ago

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
NTLA

Investor's Business Daily

6 months ago

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

NTLA

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

NTLA

MT Newswires

6 months ago

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
NTLA

GlobeNewswire

6 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
NTLA

Motley Fool

6 months ago

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Intellia Therapeutics Announces Promising CRISPR Therapy Results
NTLA

TipRanks

6 months ago

Intellia Therapeutics Announces Promising CRISPR Therapy Results

ReCode to secure funds for cystic fibrosis gene correction treatments
NTLA

Pharmaceutical Technology

6 months ago

ReCode to secure funds for cystic fibrosis gene correction treatments

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
NTLA

TipRanks

6 months ago

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

Intellia’s gene editing therapy shows early potential in rare heart condition
NTLA

Clinical Trials Arena

6 months ago

Intellia’s gene editing therapy shows early potential in rare heart condition

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
NTLA

BioPharma Dive

6 months ago

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
NTLA

GlobeNewswire

6 months ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

NTLA

Morningstar Research

6 months ago

Analyst Report: Intellia Therapeutics, Inc.

Share on Social Networks: